Cargando…

Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer Therapy

The adenylate cyclase (ADCY) superfamily is a group of glycoproteins regulating intracellular signaling. ADCYs act as key regulators in the cyclic adenosine monophosphate (cAMP) signaling pathway and are related to cell sensitivity to chemotherapy and ionizing radiation. Many members of the superfam...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Rui, Liu, Tian, Shasaltaneh, Marzieh Dehghan, Wang, Xuan, Imani, Saber, Wen, QingLian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271773/
https://www.ncbi.nlm.nih.gov/pubmed/35832555
http://dx.doi.org/10.3389/fonc.2022.829212
_version_ 1784744743678246912
author Guo, Rui
Liu, Tian
Shasaltaneh, Marzieh Dehghan
Wang, Xuan
Imani, Saber
Wen, QingLian
author_facet Guo, Rui
Liu, Tian
Shasaltaneh, Marzieh Dehghan
Wang, Xuan
Imani, Saber
Wen, QingLian
author_sort Guo, Rui
collection PubMed
description The adenylate cyclase (ADCY) superfamily is a group of glycoproteins regulating intracellular signaling. ADCYs act as key regulators in the cyclic adenosine monophosphate (cAMP) signaling pathway and are related to cell sensitivity to chemotherapy and ionizing radiation. Many members of the superfamily are detectable in most chemoresistance cases despite the complexity and unknownness of the specific mechanism underlying the role of ADCYs in the proliferation and invasion of cancer cells. The overactivation of ADCY, as well as its upstream and downstream regulators, is implicated as a major potential target of novel anticancer therapies and markers of exceptional responders to chemotherapy. The present review focuses on the oncogenic functions of the ADCY family and emphasizes the possibility of the mediating roles of deleterious nonsynonymous single nucleotide polymorphisms (nsSNPs) in ADCY as a prognostic therapeutic target in modulating resistance to chemotherapy and immunotherapy. It assesses the mediating roles of ADCY and its counterparts as stress regulators in reprogramming cancer cell metabolism and the tumor microenvironment. Additionally, the well-evaluated inhibitors of ADCY-related signaling, which are under clinical investigation, are highlighted. A better understanding of ADCY-induced signaling and deleterious nsSNPs (p.E1003K and p.R1116C) in ADCY6 provides new opportunities for developing novel therapeutic strategies in personalized oncology and new approaches to enhance chemoimmunotherapy efficacy in treating various cancers.
format Online
Article
Text
id pubmed-9271773
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92717732022-07-12 Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer Therapy Guo, Rui Liu, Tian Shasaltaneh, Marzieh Dehghan Wang, Xuan Imani, Saber Wen, QingLian Front Oncol Oncology The adenylate cyclase (ADCY) superfamily is a group of glycoproteins regulating intracellular signaling. ADCYs act as key regulators in the cyclic adenosine monophosphate (cAMP) signaling pathway and are related to cell sensitivity to chemotherapy and ionizing radiation. Many members of the superfamily are detectable in most chemoresistance cases despite the complexity and unknownness of the specific mechanism underlying the role of ADCYs in the proliferation and invasion of cancer cells. The overactivation of ADCY, as well as its upstream and downstream regulators, is implicated as a major potential target of novel anticancer therapies and markers of exceptional responders to chemotherapy. The present review focuses on the oncogenic functions of the ADCY family and emphasizes the possibility of the mediating roles of deleterious nonsynonymous single nucleotide polymorphisms (nsSNPs) in ADCY as a prognostic therapeutic target in modulating resistance to chemotherapy and immunotherapy. It assesses the mediating roles of ADCY and its counterparts as stress regulators in reprogramming cancer cell metabolism and the tumor microenvironment. Additionally, the well-evaluated inhibitors of ADCY-related signaling, which are under clinical investigation, are highlighted. A better understanding of ADCY-induced signaling and deleterious nsSNPs (p.E1003K and p.R1116C) in ADCY6 provides new opportunities for developing novel therapeutic strategies in personalized oncology and new approaches to enhance chemoimmunotherapy efficacy in treating various cancers. Frontiers Media S.A. 2022-06-27 /pmc/articles/PMC9271773/ /pubmed/35832555 http://dx.doi.org/10.3389/fonc.2022.829212 Text en Copyright © 2022 Guo, Liu, Shasaltaneh, Wang, Imani and Wen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Guo, Rui
Liu, Tian
Shasaltaneh, Marzieh Dehghan
Wang, Xuan
Imani, Saber
Wen, QingLian
Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer Therapy
title Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer Therapy
title_full Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer Therapy
title_fullStr Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer Therapy
title_full_unstemmed Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer Therapy
title_short Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer Therapy
title_sort targeting adenylate cyclase family: new concept of targeted cancer therapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271773/
https://www.ncbi.nlm.nih.gov/pubmed/35832555
http://dx.doi.org/10.3389/fonc.2022.829212
work_keys_str_mv AT guorui targetingadenylatecyclasefamilynewconceptoftargetedcancertherapy
AT liutian targetingadenylatecyclasefamilynewconceptoftargetedcancertherapy
AT shasaltanehmarziehdehghan targetingadenylatecyclasefamilynewconceptoftargetedcancertherapy
AT wangxuan targetingadenylatecyclasefamilynewconceptoftargetedcancertherapy
AT imanisaber targetingadenylatecyclasefamilynewconceptoftargetedcancertherapy
AT wenqinglian targetingadenylatecyclasefamilynewconceptoftargetedcancertherapy